Immunobiology of Primary and Metastatic CNS Cancer: Multidisciplinary Science to Advance Cancer Immunotherapy

​Continuing Medical Education (CME)


Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement
AACR has designated this live activity for a maximum of 17.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Thursday, March 29. (Link will be posted below prior to the conference.) Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.


Statement of Educational Need, Target Audience, and Learning Objectives
Primary malignant brain tumors are a major unmet clinical challenge with unknown etiology and inflammation is a critical mechanism underlying neurological disease. In addition, because of improvements in control of systemic disease and the consequent prolongation of life span, the incidence of secondary brain cancer is increasing. Therefore, both primary and secondary CNS cancers remain two of the most complicated areas of oncology and need to be better characterized in order for clinicians to be able to properly diagnose and treat patients.

The inflammatory tumor microenvironment of the brain can be a therapeutic target for vaccines and immunotherapies. Currently, immunotherapy is not a standard treatment for brain tumors, but it may provide invaluable support beyond traditional chemotherapy or radiation for eradication of cancerous cells in the brain. However, recent incidences of serious neurotoxicity in patients receiving CAR T therapy for their hematopoietic malignancy underscore the need for better understanding of interactions between the CNS and the systemic immune system.

World-recognized researchers in the fields of immunology, neuro-immunology, and neuro-oncology will update physicians about the hallmarks, mechanisms and outcomes of CNS tumor invasion, advances and challenges in immunotherapy treatment modalities, new viral therapies, and immunobiology of the CNS. Attendees will also be updated on relevant fields such as novel therapeutic agents that can be used in CNS tumor therapy and/or prevention, technologies in molecular biology, proteomics, engineering, and imaging that are providing novel insights into better understanding of CNS tumor biology and immunology.

In order for physicians to improve outcomes of primary and metastatic CNS tumors, they should ideally understand the disease from multiple perspectives. This conference will bring together the physicians who are treating the patients for primary disease, adverse reactions to treatment, and resistance to treatment with the scientists who are studying the mechanisms at the transcriptional, proteomic, and epigenetic levels; using mouse models, enhanced and novel imaging techniques, next-generation sequencing, or researching whole systems. Clinicians should come away with a better knowledge of how to characterize CNS tumors, treat such tumors, and anticipate adverse reactions

After participating in this CME activity, physicians should be able to:

  1. Identify and integrate novel strategies for visualizing and treating brain tumors.
  2. Evaluate novel biomarkers or neoantigens, and genomics to assess patients' individual cancer, potential responses to treatment, and to personalize therapy.
  3. Explain the role of inflammation in CNS tumor metastasis.
  4. Explain the role of immunomodulatory cells in inflammation, metastasis, and the tumor microenvironment.
  5. Integrate novel viral therapies, multi-modality therapies, checkpoint blockades, and engineered immune cells for personalizing cancer immune responses.
  6. Detect and assess neurotoxicities as a result of immunotherapy.

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Acknowledgment of Financial or Other Support 
This activity is supported by Professional Educational Grants from [Company Names in alpha order]. Any others will be disclosed at the activity.

Questions about CME?
Please contact the Office of CME at (215) 440-9300 or